{"id":10536,"date":"2026-08-17T10:29:44","date_gmt":"2026-08-17T01:29:44","guid":{"rendered":"https:\/\/kojihifu.com\/english\/?p=10536"},"modified":"2026-08-17T12:33:14","modified_gmt":"2026-08-17T03:33:14","slug":"cholesterol-without-statins-japan","status":"publish","type":"post","link":"https:\/\/kojihifu.com\/english\/cholesterol-without-statins-japan\/","title":{"rendered":"Cholesterol Without Statins: A Nutritional Approach in Japan"},"content":{"rendered":"

By Dr. Jun Karibe, MD<\/strong> \u2014 BIOTOPE Clinic Shirokanedai, Tokyo \u00a0\u00b7\u00a0 Reviewed August 2026<\/p>\n

A patient walks into our BIOTOPE Clinic<\/strong> in Shirokanedai carrying an annual kenshin report.<\/p>\n

The LDL cholesterol number<\/strong> is circled in red. It reads 148 mg\/dL. The occupational-health physician has spent five minutes with them, written a referral to a cardiology outpatient clinic for statin therapy, and moved on to the next patient in the queue.<\/p>\n

The patient is 43 years old, exercises three times a week, has no family history of early heart disease, and has never been told what their ApoB, Lp(a), or particle size looks like. They come to us with one question: is there another way?<\/p>\n

This is one of the most common consultations we run for the English-speaking community<\/strong> in Tokyo.<\/p>\n

It sits in a difficult space. Statins are one of the most rigorously studied classes of drug in the history of medicine, and in the right patient they save lives. They are also over-prescribed to low-risk patients based on a single LDL number, and they are sometimes withheld from patients who genuinely need them. Neither reflex \u2014 automatic prescription or automatic refusal \u2014 reflects honest medicine.<\/p>\n

This article walks through what we actually know about cholesterol in 2026, why an isolated LDL number is a poor risk instrument, which advanced lipid markers change the conversation, when statin therapy is unambiguously indicated, when a well-executed nutritional approach is reasonable, and what the evidence looks like for each nutritional lever available to a patient in Japan. It is written for the informed adult who wants to make a considered decision rather than either accept a prescription reflexively or dismiss one out of hand.<\/p>\n

What the kenshin lipid panel actually tells you<\/h2>\n
\"cholesterol<\/figure>\n

A Japanese annual health check typically reports four lipid values<\/strong>: total cholesterol, LDL cholesterol (usually calculated by the Friedewald equation from the other three), HDL cholesterol, and triglycerides.<\/p>\n

The reference ranges used across most Japanese laboratories consider LDL under 120 mg\/dL as normal, 120 to 139 mg\/dL as borderline, and 140 mg\/dL or above as elevated. Total cholesterol under 220 mg\/dL is treated as normal. Triglycerides under 150 mg\/dL fasting are considered normal. HDL above 40 mg\/dL is considered normal, with sex-specific nuances.<\/p>\n

These four numbers are cheap to measure, universally available, and were established as the operational risk framework in the 1980s when the epidemiology of cardiovascular disease was first being mapped. The problem is that lipid science has moved on considerably in the four decades since, and the four-number panel now captures perhaps half of the useful information about a patient’s actual atherogenic risk. Two patients with an identical LDL of 145 mg\/dL can carry substantially different cardiovascular risk depending on the number of LDL particles they carry, the size of those particles, their Lp(a) level, their inflammatory burden, and their metabolic context.<\/p>\n

The isolated LDL number is a proxy, not a diagnosis. When a patient walks in with a red-circled LDL and no other data, the honest first step is to gather the data that changes the risk picture \u2014 not to prescribe or refuse a drug on the basis of an incomplete panel.<\/p>\n

The markers that actually predict cardiovascular events<\/h2>\n
\"cholesterol<\/figure>\n

Four measurements, none of which appear on a standard kenshin, do more work than LDL alone.<\/p>\n

Apolipoprotein B (ApoB)<\/h3>\n

Every atherogenic particle in the bloodstream \u2014 LDL, VLDL, IDL, chylomicron remnants, and Lp(a) \u2014 carries exactly one molecule of ApoB on its surface. Measuring serum ApoB therefore tells you the total number of atherogenic particles you carry, which is a more direct measure of the biological process that causes atherosclerosis than the cholesterol content those particles happen to be carrying. A patient with an LDL of 130 mg\/dL but a low ApoB has fewer, larger, cholesterol-rich particles and a lower event risk than a patient with the same LDL and a high ApoB reflecting many small, dense particles.<\/p>\n

Recent Mendelian randomisation work and prospective cohort analyses through 2024 continue to support ApoB as a superior predictor of coronary events compared with LDL-C, particularly in patients with metabolic syndrome, prediabetes, or high triglycerides.[1]<\/sup> A functional target for ApoB in primary prevention is generally below 90 mg\/dL, with tighter targets applied for patients with existing coronary disease or diabetes.<\/p>\n

Lipoprotein(a) \u2014 Lp(a)<\/h3>\n

Lp(a) is an LDL-like particle with an additional apolipoprotein \u2014 apo(a) \u2014 attached. It is heavily genetically determined, does not respond meaningfully to diet or exercise, and elevates lifetime cardiovascular risk approximately in proportion to its concentration. Roughly one in five adults carries an elevated Lp(a), typically defined as above 50 mg\/dL or 125 nmol\/L, and most of these patients have no idea because Lp(a) is almost never measured on a standard panel.<\/p>\n

A single lifetime Lp(a) measurement is a reasonable investment for anyone with a family history of early cardiovascular disease, a personal history of premature coronary events, or an unexplained elevation of LDL that does not fit dietary context. The 2024 European Atherosclerosis Society consensus recommends universal Lp(a) screening at least once in adulthood, and clinical practice in Japan is slowly catching up.[2]<\/sup><\/p>\n

High-sensitivity C-reactive protein (hs-CRP)<\/h3>\n

Atherosclerosis<\/strong> is an inflammatory disease. hs-CRP, a measure of low-grade systemic inflammation, refines cardiovascular risk on top of the lipid panel. The MESA study and subsequent large cohorts have shown that patients with elevated hs-CRP (above 2 mg\/L) but moderate LDL carry event risk comparable to patients with high LDL but low hs-CRP.[3]<\/sup> A patient whose LDL sits at 140 mg\/dL but whose hs-CRP is under 1 mg\/L is a very different clinical proposition from a patient with the same LDL and an hs-CRP of 4 mg\/L.<\/p>\n

LDL particle size and number<\/h3>\n

Where available \u2014 NMR-based lipid subfractionation is offered by a small number of Japanese specialty laboratories \u2014 the distinction between pattern A (large, buoyant LDL particles) and pattern B (small, dense LDL particles) further refines risk.<\/p>\n

Pattern B carries substantially higher atherogenic potential per unit of LDL cholesterol, and it clusters with insulin resistance, elevated triglycerides, and low HDL. This is why the triglyceride-to-HDL ratio \u2014 a number any patient can calculate from a standard panel \u2014 is a useful bedside proxy for the small-dense LDL pattern. A ratio above 3 (in mg\/dL units) suggests a more atherogenic lipid profile than the LDL number alone would imply.<\/p>\n

When statins are the right call<\/h2>\n
\"cholesterol<\/figure>\n

Nothing that follows in this article should be read as an argument against statins. Statin therapy has one of the strongest evidence bases in medicine, and there are patient populations for whom the risk-benefit calculation is not close and the answer is clearly to treat.<\/p>\n

Secondary prevention<\/h3>\n

Any patient with established atherosclerotic cardiovascular disease \u2014 a prior myocardial infarction, prior stroke of atherosclerotic origin, prior coronary revascularisation, symptomatic peripheral artery disease, or documented significant coronary stenosis on imaging \u2014 belongs on high-intensity statin therapy unless there is a specific contraindication.<\/p>\n

The absolute risk reduction from statins in secondary prevention is large, the number needed to treat is modest, and every meta-analysis of the last two decades converges on the same conclusion. This is not a conversation about nutritional alternatives.<\/p>\n

Familial hypercholesterolaemia<\/h3>\n

Patients with heterozygous familial hypercholesterolaemia (HeFH) carry lifetime LDL exposure that produces cardiovascular events in the fourth or fifth decade if untreated. LDL levels above 190 mg\/dL untreated, particularly when accompanied by a family history of early coronary disease or physical stigmata such as tendon xanthomas, warrant urgent evaluation and typically statin therapy from a young age. Diet and lifestyle contribute but cannot substitute for pharmacological LDL lowering in this population.<\/p>\n

Diabetes with additional risk factors<\/h3>\n

Most patients with type 2 diabetes above age 40, and many with type 1 diabetes of long duration, benefit meaningfully from statin therapy for primary prevention. The absolute risk reduction is large enough that guidelines from the American Diabetes Association, the European Society of Cardiology, and the Japan Atherosclerosis Society all recommend statins for the great majority of adult diabetic patients.<\/p>\n

Elevated calculated risk<\/h3>\n

For a patient without any of the above but with a calculated 10-year atherosclerotic cardiovascular disease (ASCVD) risk above roughly 7.5 to 10 percent, guidelines generally favour statin therapy after a shared decision-making conversation. The calculation should incorporate age, sex, smoking status, blood pressure, diabetes, and lipid values. In practice this means many men over 55 and many post-menopausal women with additional risk factors sit in a range where statins are the guideline-supported default.<\/p>\n

In each of these categories, the honest role of a physician who practises nutritional medicine is to reinforce the statin recommendation, work on the underlying dietary and metabolic drivers alongside the pharmacology, and manage the patient’s questions and concerns about the drug. Refusing statins in a genuine secondary-prevention patient because “nutrition can handle it” is not integrative medicine. It is malpractice.<\/p>\n

When a nutritional approach is genuinely reasonable<\/h2>\n
\"cholesterol<\/figure>\n

Between the clear indications above and the low-risk patient with a borderline number lies a<\/strong> substantial group of adults for whom a nutritional and lifestyle approach \u2014 pursued seriously and monitored properly \u2014 is a defensible first step. The characteristic profile looks something like this:<\/p>\n